Attention-Deficit/Hyperactivity Disorder (ADHD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Attention-deficit/hyperactivity disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and hyperactivity-impulsivity that interferes with functioning or development. ADHD is a group of behaviors. It is also called attention deficit disorder (ADD). Attention deficit hyperactivity disorder (ADHD) is a behavioral disorder that includes inattentiveness, hyperactivity, and impulsiveness symptoms. ADHD symptoms are generally noticed at a young age and may become more noticeable as a child's circumstances vary, such as when they start school. The majority of cases are found when children are between six and twelve. ADHD symptoms generally improve with age, but many adults diagnosed with the condition at a young age continue to struggle. People who have ADHD may also suffer from sleep and anxiety disorders. Individuals with ADHD may also work with attention, executive function, and working memory. Executive function deficits have recently emerged as critical factors influencing academic and career success. The ability of the brain to prioritize and manage thoughts and actions is referred to as executive function.

 

The prevalence of cases of Attention-deficit/hyperactivity disorder (ADHD) ranges from 5 MN to 6.5 MN in the USA.

 

The competitive landscape of Attention-Deficit/Hyperactivity Disorder (ADHD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights on Attention-Deficit/Hyperactivity Disorder (ADHD) across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Attention-Deficit/Hyperactivity Disorder (ADHD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Attention-Deficit/Hyperactivity Disorder (ADHD)– Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          TD-9855           Theravance Biopharma  Phase 2

2          MG01CI            Alcobra Ltd.      Phase 3

3          Centanafadine Hydrochloride     Otsuka Pharmaceutical Development & Commercialization, Inc.  Phase 3

4          Methylphenidate MPH   Mensia Technologies SA           Phase 2

5          Lisdexamfetamine         Shire    Phase 2

6          V81444 Vernalis (R&D) Ltd        Phase 2

7          ND0801            NeuroDerm Ltd. Phase 2

8          Dasotraline       Sunovion          Phase 3

9          PDC-1421 Capsule        BioLite, Inc.       Phase 2

10        SPN-812           Supernus Pharmaceuticals, Inc. Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more